Articular cartilage gene therapy with recombinant vector encoding BMP-7
The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of osteoarthritis in mammals, advantageously in humans, dogs, horses and cats, by intra-articular administration of the recombinant vectors and pharmaceutical compositions of the invention.
1. A method of treating a mammalian subject suffering from osteoarthritis, comprising administering intra-articularly to said mammalian subject a therapeutically effective amount of a composition comprising at least one pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle and recombinant adenovirus vectors comprising a polynucleotide encoding a BMP-7 polypeptide having the sequence as set forth in SEQ ID NO: 3 operatively linked to a promoter.
2. The method of claim 1 , wherein the BMP-7 polynucleotide has the sequence as set forth in SEQ ID NO: 2.
3. The method according to claim 1 , or 2 , wherein the recombinant adenovirus vectors are human adenoviruses.
4. The method according to claim 3 , wherein the human adenoviruses are human adenoviruses type 5 (hAd5).
5. The method according to claim 4 , wherein the human adenoviruses type 5 (hAd5) are PEGylated.
6. The method according to claim 1 , or 2 , wherein the recombinant adenovirus vectors are canine adenoviruses.
7. The method according to claim 6 , wherein the canine adenoviruses are canine adenoviruses type 2 (CAV2).
8. The method according to claim 1 , or 2 , wherein the mammalian subject is selected from the group consisting of human, canidae, equidae and felidae.
9. The method according to claim 1 , or 2 , wherein the mammalian subject is a dog, a bitch or a puppy.
10. The method according to claim 1 , or 2 , wherein the mammalian subject is a cat or a kitten.
11. The method according to claim 1 , or 2 , wherein the mammalian subject is a horse, a mare or a foal.
12. The method according to claim 1 , or 2 , wherein the promoter is selected from the group consisting of a CMV IE promoter, a RSV promoter, an HSV-1 TK promoter, a SV40 early promoter, a SV40 late promoter, an adenovirus major late promoter, a phosphoglycerate kinase gene promoter, a metallothionein gene promoter, an α-1 antitrypsin gene promoter, an albumin gene promoter, a collagenase gene promoter, an elastase I gene promoter, a β-actin gene promoter, a β-globin gene promoter, a γ-globin gene promoter, an α-fetoprotein gene promoter, and a muscle creatine kinase gene promoter.